A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis [IPF] (NCT06967805)

WISPer

This trial is Currently recruiting
Registration number NCT06967805
The study is being done over 24 weeks to see whether an experimental drug called MTX-463 can slow or stop a lung disease called idiopathic pulmonary fibrosis (IPF) from worsening, in people >40 years of age who have IPF.

Program & service

This trial is being run with the Heart & Lung service, and as part of the Respiratory program.

Trial phase

Phase 2

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

A/Prof Ian Glaspole

Key inclusion data

Over 40yrs; Diagnosed with IPF; FVC of ?45 DLCO of ?25.

More information

To find out more about this clinical trial, please review full details on the ANZCTR website.

View on ANZCTR

If you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.